Heart Failure Association of the European Society of Cardiology update on sodium–glucose co-transporter 2 inhibitors in heart failure

Petar M. Seferović; Gabriele Fragasso; Mark Petrie; Wilfried Mullens; Roberto Ferrari; Thomas Thum; Johann Bauersachs; Stefan D. Anker; Robin Ray; Yuksel Çavuşoğlu; Marija Polovina; Marco Metra; Giuseppe Ambrosio; Krishna Prasad; Jelena Seferović; Pardeep S. Jhund; Giuseppe Dattilo; Jelena Čelutkiene; Massimo Piepoli; Brenda Moura; Ovidiu Chioncel; Tuvia Ben Gal; Stephane Heymans; Tiny Jaarsma; Loreena Hill; Yuri Lopatin; Alexander R. Lyon; Piotr Ponikowski; Mitja Lainščak; Ewa Jankowska; Christian Mueller; Francesco Cosentino; Lars H. Lund; Gerasimos S. Filippatos; Frank Ruschitzka; Andrew J.S. Coats; Giuseppe M.C. Rosano

doi:10.1002/ejhf.2026

Heart Failure Association of the European Society of Cardiology update on sodium–glucose co-transporter 2 inhibitors in heart failure

Petar M. Seferović^*, Gabriele Fragasso, Mark Petrie, Wilfried Mullens, Roberto Ferrari, Thomas Thum, Johann Bauersachs, Stefan D. Anker, Robin Ray, Yuksel Çavuşoğlu, Marija Polovina, Marco Metra, Giuseppe Ambrosio, Krishna Prasad, Jelena Seferović, Pardeep S. Jhund, Giuseppe Dattilo, Jelena Čelutkiene, Massimo Piepoli, Brenda MouraOvidiu Chioncel, Tuvia Ben Gal, Stephane Heymans, Tiny Jaarsma, Loreena Hill, Yuri Lopatin, Alexander R. Lyon, Piotr Ponikowski, Mitja Lainščak, Ewa Jankowska, Christian Mueller, Francesco Cosentino, Lars H. Lund, Gerasimos S. Filippatos, Frank Ruschitzka, Andrew J.S. Coats, Giuseppe M.C. Rosano

^*Corresponding author for this work

School of Nursing and Midwifery

Research output: Contribution to journal › Article › peer-review

23 Citations (Scopus)

Abstract

The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium–glucose co-transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given:. • Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin are recommended for the prevention of HF hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or at high cardiovascular risk. • Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalization and cardiovascular death in symptomatic patients with HF and reduced ejection fraction already receiving guideline-directed medical therapy regardless of the presence of type 2 diabetes mellitus.

Original language	English
Pages (from-to)	1984-1986
Number of pages	3
Journal	European Journal of Heart Failure
Volume	22
Issue number	11
Early online date	27 Oct 2020
DOIs	https://doi.org/10.1002/ejhf.2026
Publication status	Published - 29 Nov 2020

Bibliographical note

Funding Information:
P.M.S. reports honorarium for lecture from Medtronic, Abbott, Servier, AstraZeneca, Respicardia; consultancy agreement and honorarium for lecture from Boehringer Ingelheim, Novartis; and consultancy agreement from Vifor Pharma. M.P. reports grants and personal fees from AstraZeneca, Novartis, Novo Nordisk, Boehringer Ingelheim, Abbvie, Takeda, Bayer, Pharmacosmos; personal fees from Vifor, Cardiorentis, Alnylam, outside the submitted work. R.F. reports personal fees from Servier International, Merck Serono, Pfizer, DOC Generici, Società Prodotti Antibiotici Spa; grants and personal fees from Novartis, outside the submitted work. T.T. reports personal fees and other from Cardior Pharmaceuticals GmbH, outside the submitted work. J.B. reports personal fees from Abbott, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, MSD, Novartis, Pfizer, Servier; grants and personal fees from Abiomed, CvRX, Vifor, Zoll, outside the submitted work. M.P. reports honorarium for lecture from Boehringer Ingelheim, outside the submitted work. M.M. reports personal fees from minimal amount honoraria from AstraZeneca, Abbott Vascular, Bayer, Edwards Therapeutics, Vifor Pharma for participation in trials' committees or public speeches, outside the submitted work. J.Č. reports personal fees from AstraZeneca, Boehringer Ingelheim, Novartis, Servier, Amgen, outside the submitted work. L.H. reports personal fees from Novartis, outside the submitted work. A.R.L. reports personal fees from Ferring Pharmaceuticals, Eli Lily, Bristol Myers Squibb, Eisai Ltd, Myocardial Solutions and Heartfelt Technologies. C.M. reports personal fees from AstraZeneca, Boehringer Ingelheim, outside the submitted work. L.H.L. reports personal fees from Merck, Sanofi, Bayer, Pharmacosmos, Abbott, Medscape, Myokardia; grants and personal fees from Vifor‐Fresenius, AstraZeneca, Relypsa, Novartis, Mundipharma, Boehringer Ingelheim; grants from Boston Scientific, outside the submitted work. G.S.F. reports other from Committee Member in trials sponsored by Medtronic, Vifor, Servier, Novartis, BI, outside the submitted work. F.R. since 1 January 2018: no personal payments; all payments directly to the University of Zurich; before 2018: reports grants and personal fees from SJM/Abbott, Servier, Novartis, Bayer; personal fees from Zoll, AstraZeneca, Sanofi, Amgen, BMS, Pfizer, Fresenius, Vifor, Roche, Cardiorentis, Boehringer Ingelheim; other from Heartware, grants from Mars, outside the submitted work. F.C. reports personal fees from Novo Nordisk, MSD, Pfizer, Mundipharma, Lilly, AstraZeneca, BMS, outside the submitted work. A.J.S.C. reports personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Menarini, Novartis, Nutricia, Servier, Vifor, Actimed, Arena, Cardiac Dimensions, Corvia, CVRx, Enopace, ESN Cleer, Faraday, Gore, Impulse Dynamics, Respicardia, outside the submitted work, S.D.A. reports grants and personal fees from Vifor Int, Abbott Vascular; personal fees from Bayer, Boehringer Ingelheim, Novartis, Servier, Impulse Dynamics, Cardiac Dimensions, outside the submitted work. P.P. reports personal fees and other from Boehringer Ingelheim, AstraZeneca, during the conduct of the study; personal fees and other from Amgen, Novartis, Servier, Bayer, BMS, Vifor Pharma, Renal Guard Solutions, Impulse Dynamics, personal fees from Pfizer, Berlin Chemie, outside the submitted work. B.M. reports personal fees from Boehringer Ingelheim, AstraZeneca, outside the submitted work. M.L. reports personal fees from AstraZeneca, Boehringer Ingelheim, during the conduct of the study. All other authors have noting to disclose. Conflict of interest:

Publisher Copyright:
© 2020 European Society of Cardiology

Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.

Keywords

Cardiovascular outcomes
Heart failure
Renal function
Sodium–glucose co-transporter 2 inhibitors
Type 2 diabetes mellitus

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/ejhf.2026Licence: Unspecified

Cite this

Seferović, P. M., Fragasso, G., Petrie, M., Mullens, W., Ferrari, R., Thum, T., Bauersachs, J., Anker, S. D., Ray, R., Çavuşoğlu, Y., Polovina, M., Metra, M., Ambrosio, G., Prasad, K., Seferović, J., Jhund, P. S., Dattilo, G., Čelutkiene, J., Piepoli, M., ... Rosano, G. M. C. (2020). Heart Failure Association of the European Society of Cardiology update on sodium–glucose co-transporter 2 inhibitors in heart failure. European Journal of Heart Failure, 22(11), 1984-1986. https://doi.org/10.1002/ejhf.2026

Seferović, Petar M. ; Fragasso, Gabriele ; Petrie, Mark ; Mullens, Wilfried ; Ferrari, Roberto ; Thum, Thomas ; Bauersachs, Johann ; Anker, Stefan D. ; Ray, Robin ; Çavuşoğlu, Yuksel ; Polovina, Marija ; Metra, Marco ; Ambrosio, Giuseppe ; Prasad, Krishna ; Seferović, Jelena ; Jhund, Pardeep S. ; Dattilo, Giuseppe ; Čelutkiene, Jelena ; Piepoli, Massimo ; Moura, Brenda ; Chioncel, Ovidiu ; Ben Gal, Tuvia ; Heymans, Stephane ; Jaarsma, Tiny ; Hill, Loreena ; Lopatin, Yuri ; Lyon, Alexander R. ; Ponikowski, Piotr ; Lainščak, Mitja ; Jankowska, Ewa ; Mueller, Christian ; Cosentino, Francesco ; Lund, Lars H. ; Filippatos, Gerasimos S. ; Ruschitzka, Frank ; Coats, Andrew J.S. ; Rosano, Giuseppe M.C. / Heart Failure Association of the European Society of Cardiology update on sodium–glucose co-transporter 2 inhibitors in heart failure. In: European Journal of Heart Failure. 2020 ; Vol. 22, No. 11. pp. 1984-1986.

@article{3cc8eaa204584758b3c24035b4ad618d,

title = "Heart Failure Association of the European Society of Cardiology update on sodium–glucose co-transporter 2 inhibitors in heart failure",

abstract = "The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium–glucose co-transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given:. • Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin are recommended for the prevention of HF hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or at high cardiovascular risk. • Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalization and cardiovascular death in symptomatic patients with HF and reduced ejection fraction already receiving guideline-directed medical therapy regardless of the presence of type 2 diabetes mellitus.",

keywords = "Cardiovascular outcomes, Heart failure, Renal function, Sodium–glucose co-transporter 2 inhibitors, Type 2 diabetes mellitus",

author = "Seferovi{\'c}, {Petar M.} and Gabriele Fragasso and Mark Petrie and Wilfried Mullens and Roberto Ferrari and Thomas Thum and Johann Bauersachs and Anker, {Stefan D.} and Robin Ray and Yuksel {\c C}avu{\c s}oğlu and Marija Polovina and Marco Metra and Giuseppe Ambrosio and Krishna Prasad and Jelena Seferovi{\'c} and Jhund, {Pardeep S.} and Giuseppe Dattilo and Jelena {\v C}elutkiene and Massimo Piepoli and Brenda Moura and Ovidiu Chioncel and {Ben Gal}, Tuvia and Stephane Heymans and Tiny Jaarsma and Loreena Hill and Yuri Lopatin and Lyon, {Alexander R.} and Piotr Ponikowski and Mitja Lain{\v s}{\v c}ak and Ewa Jankowska and Christian Mueller and Francesco Cosentino and Lund, {Lars H.} and Filippatos, {Gerasimos S.} and Frank Ruschitzka and Coats, {Andrew J.S.} and Rosano, {Giuseppe M.C.}",

note = "Funding Information: P.M.S. reports honorarium for lecture from Medtronic, Abbott, Servier, AstraZeneca, Respicardia; consultancy agreement and honorarium for lecture from Boehringer Ingelheim, Novartis; and consultancy agreement from Vifor Pharma. M.P. reports grants and personal fees from AstraZeneca, Novartis, Novo Nordisk, Boehringer Ingelheim, Abbvie, Takeda, Bayer, Pharmacosmos; personal fees from Vifor, Cardiorentis, Alnylam, outside the submitted work. R.F. reports personal fees from Servier International, Merck Serono, Pfizer, DOC Generici, Societ{\`a} Prodotti Antibiotici Spa; grants and personal fees from Novartis, outside the submitted work. T.T. reports personal fees and other from Cardior Pharmaceuticals GmbH, outside the submitted work. J.B. reports personal fees from Abbott, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, MSD, Novartis, Pfizer, Servier; grants and personal fees from Abiomed, CvRX, Vifor, Zoll, outside the submitted work. M.P. reports honorarium for lecture from Boehringer Ingelheim, outside the submitted work. M.M. reports personal fees from minimal amount honoraria from AstraZeneca, Abbott Vascular, Bayer, Edwards Therapeutics, Vifor Pharma for participation in trials' committees or public speeches, outside the submitted work. J.{\v C}. reports personal fees from AstraZeneca, Boehringer Ingelheim, Novartis, Servier, Amgen, outside the submitted work. L.H. reports personal fees from Novartis, outside the submitted work. A.R.L. reports personal fees from Ferring Pharmaceuticals, Eli Lily, Bristol Myers Squibb, Eisai Ltd, Myocardial Solutions and Heartfelt Technologies. C.M. reports personal fees from AstraZeneca, Boehringer Ingelheim, outside the submitted work. L.H.L. reports personal fees from Merck, Sanofi, Bayer, Pharmacosmos, Abbott, Medscape, Myokardia; grants and personal fees from Vifor‐Fresenius, AstraZeneca, Relypsa, Novartis, Mundipharma, Boehringer Ingelheim; grants from Boston Scientific, outside the submitted work. G.S.F. reports other from Committee Member in trials sponsored by Medtronic, Vifor, Servier, Novartis, BI, outside the submitted work. F.R. since 1 January 2018: no personal payments; all payments directly to the University of Zurich; before 2018: reports grants and personal fees from SJM/Abbott, Servier, Novartis, Bayer; personal fees from Zoll, AstraZeneca, Sanofi, Amgen, BMS, Pfizer, Fresenius, Vifor, Roche, Cardiorentis, Boehringer Ingelheim; other from Heartware, grants from Mars, outside the submitted work. F.C. reports personal fees from Novo Nordisk, MSD, Pfizer, Mundipharma, Lilly, AstraZeneca, BMS, outside the submitted work. A.J.S.C. reports personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Menarini, Novartis, Nutricia, Servier, Vifor, Actimed, Arena, Cardiac Dimensions, Corvia, CVRx, Enopace, ESN Cleer, Faraday, Gore, Impulse Dynamics, Respicardia, outside the submitted work, S.D.A. reports grants and personal fees from Vifor Int, Abbott Vascular; personal fees from Bayer, Boehringer Ingelheim, Novartis, Servier, Impulse Dynamics, Cardiac Dimensions, outside the submitted work. P.P. reports personal fees and other from Boehringer Ingelheim, AstraZeneca, during the conduct of the study; personal fees and other from Amgen, Novartis, Servier, Bayer, BMS, Vifor Pharma, Renal Guard Solutions, Impulse Dynamics, personal fees from Pfizer, Berlin Chemie, outside the submitted work. B.M. reports personal fees from Boehringer Ingelheim, AstraZeneca, outside the submitted work. M.L. reports personal fees from AstraZeneca, Boehringer Ingelheim, during the conduct of the study. All other authors have noting to disclose. Conflict of interest: Publisher Copyright: {\textcopyright} 2020 European Society of Cardiology Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2020",

month = nov,

day = "29",

doi = "10.1002/ejhf.2026",

language = "English",

volume = "22",

pages = "1984--1986",

journal = "European Journal of Heart Failure",

issn = "1388-9842",

publisher = "Oxford University Press",

number = "11",

}

Seferović, PM, Fragasso, G, Petrie, M, Mullens, W, Ferrari, R, Thum, T, Bauersachs, J, Anker, SD, Ray, R, Çavuşoğlu, Y, Polovina, M, Metra, M, Ambrosio, G, Prasad, K, Seferović, J, Jhund, PS, Dattilo, G, Čelutkiene, J, Piepoli, M, Moura, B, Chioncel, O, Ben Gal, T, Heymans, S, Jaarsma, T, Hill, L, Lopatin, Y, Lyon, AR, Ponikowski, P, Lainščak, M, Jankowska, E, Mueller, C, Cosentino, F, Lund, LH, Filippatos, GS, Ruschitzka, F, Coats, AJS & Rosano, GMC 2020, 'Heart Failure Association of the European Society of Cardiology update on sodium–glucose co-transporter 2 inhibitors in heart failure', European Journal of Heart Failure, vol. 22, no. 11, pp. 1984-1986. https://doi.org/10.1002/ejhf.2026

Heart Failure Association of the European Society of Cardiology update on sodium–glucose co-transporter 2 inhibitors in heart failure. / Seferović, Petar M.; Fragasso, Gabriele; Petrie, Mark; Mullens, Wilfried; Ferrari, Roberto; Thum, Thomas; Bauersachs, Johann; Anker, Stefan D.; Ray, Robin; Çavuşoğlu, Yuksel; Polovina, Marija; Metra, Marco; Ambrosio, Giuseppe; Prasad, Krishna; Seferović, Jelena; Jhund, Pardeep S.; Dattilo, Giuseppe; Čelutkiene, Jelena; Piepoli, Massimo; Moura, Brenda; Chioncel, Ovidiu; Ben Gal, Tuvia; Heymans, Stephane; Jaarsma, Tiny; Hill, Loreena; Lopatin, Yuri; Lyon, Alexander R.; Ponikowski, Piotr; Lainščak, Mitja; Jankowska, Ewa; Mueller, Christian; Cosentino, Francesco; Lund, Lars H.; Filippatos, Gerasimos S.; Ruschitzka, Frank; Coats, Andrew J.S.; Rosano, Giuseppe M.C.

In: European Journal of Heart Failure, Vol. 22, No. 11, 29.11.2020, p. 1984-1986.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Heart Failure Association of the European Society of Cardiology update on sodium–glucose co-transporter 2 inhibitors in heart failure

AU - Seferović, Petar M.

AU - Fragasso, Gabriele

AU - Petrie, Mark

AU - Mullens, Wilfried

AU - Ferrari, Roberto

AU - Thum, Thomas

AU - Bauersachs, Johann

AU - Anker, Stefan D.

AU - Ray, Robin

AU - Çavuşoğlu, Yuksel

AU - Polovina, Marija

AU - Metra, Marco

AU - Ambrosio, Giuseppe

AU - Prasad, Krishna

AU - Seferović, Jelena

AU - Jhund, Pardeep S.

AU - Dattilo, Giuseppe

AU - Čelutkiene, Jelena

AU - Piepoli, Massimo

AU - Moura, Brenda

AU - Chioncel, Ovidiu

AU - Ben Gal, Tuvia

AU - Heymans, Stephane

AU - Jaarsma, Tiny

AU - Hill, Loreena

AU - Lopatin, Yuri

AU - Lyon, Alexander R.

AU - Ponikowski, Piotr

AU - Lainščak, Mitja

AU - Jankowska, Ewa

AU - Mueller, Christian

AU - Cosentino, Francesco

AU - Lund, Lars H.

AU - Filippatos, Gerasimos S.

AU - Ruschitzka, Frank

AU - Coats, Andrew J.S.

AU - Rosano, Giuseppe M.C.

N1 - Funding Information: P.M.S. reports honorarium for lecture from Medtronic, Abbott, Servier, AstraZeneca, Respicardia; consultancy agreement and honorarium for lecture from Boehringer Ingelheim, Novartis; and consultancy agreement from Vifor Pharma. M.P. reports grants and personal fees from AstraZeneca, Novartis, Novo Nordisk, Boehringer Ingelheim, Abbvie, Takeda, Bayer, Pharmacosmos; personal fees from Vifor, Cardiorentis, Alnylam, outside the submitted work. R.F. reports personal fees from Servier International, Merck Serono, Pfizer, DOC Generici, Società Prodotti Antibiotici Spa; grants and personal fees from Novartis, outside the submitted work. T.T. reports personal fees and other from Cardior Pharmaceuticals GmbH, outside the submitted work. J.B. reports personal fees from Abbott, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, MSD, Novartis, Pfizer, Servier; grants and personal fees from Abiomed, CvRX, Vifor, Zoll, outside the submitted work. M.P. reports honorarium for lecture from Boehringer Ingelheim, outside the submitted work. M.M. reports personal fees from minimal amount honoraria from AstraZeneca, Abbott Vascular, Bayer, Edwards Therapeutics, Vifor Pharma for participation in trials' committees or public speeches, outside the submitted work. J.Č. reports personal fees from AstraZeneca, Boehringer Ingelheim, Novartis, Servier, Amgen, outside the submitted work. L.H. reports personal fees from Novartis, outside the submitted work. A.R.L. reports personal fees from Ferring Pharmaceuticals, Eli Lily, Bristol Myers Squibb, Eisai Ltd, Myocardial Solutions and Heartfelt Technologies. C.M. reports personal fees from AstraZeneca, Boehringer Ingelheim, outside the submitted work. L.H.L. reports personal fees from Merck, Sanofi, Bayer, Pharmacosmos, Abbott, Medscape, Myokardia; grants and personal fees from Vifor‐Fresenius, AstraZeneca, Relypsa, Novartis, Mundipharma, Boehringer Ingelheim; grants from Boston Scientific, outside the submitted work. G.S.F. reports other from Committee Member in trials sponsored by Medtronic, Vifor, Servier, Novartis, BI, outside the submitted work. F.R. since 1 January 2018: no personal payments; all payments directly to the University of Zurich; before 2018: reports grants and personal fees from SJM/Abbott, Servier, Novartis, Bayer; personal fees from Zoll, AstraZeneca, Sanofi, Amgen, BMS, Pfizer, Fresenius, Vifor, Roche, Cardiorentis, Boehringer Ingelheim; other from Heartware, grants from Mars, outside the submitted work. F.C. reports personal fees from Novo Nordisk, MSD, Pfizer, Mundipharma, Lilly, AstraZeneca, BMS, outside the submitted work. A.J.S.C. reports personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Menarini, Novartis, Nutricia, Servier, Vifor, Actimed, Arena, Cardiac Dimensions, Corvia, CVRx, Enopace, ESN Cleer, Faraday, Gore, Impulse Dynamics, Respicardia, outside the submitted work, S.D.A. reports grants and personal fees from Vifor Int, Abbott Vascular; personal fees from Bayer, Boehringer Ingelheim, Novartis, Servier, Impulse Dynamics, Cardiac Dimensions, outside the submitted work. P.P. reports personal fees and other from Boehringer Ingelheim, AstraZeneca, during the conduct of the study; personal fees and other from Amgen, Novartis, Servier, Bayer, BMS, Vifor Pharma, Renal Guard Solutions, Impulse Dynamics, personal fees from Pfizer, Berlin Chemie, outside the submitted work. B.M. reports personal fees from Boehringer Ingelheim, AstraZeneca, outside the submitted work. M.L. reports personal fees from AstraZeneca, Boehringer Ingelheim, during the conduct of the study. All other authors have noting to disclose. Conflict of interest: Publisher Copyright: © 2020 European Society of Cardiology Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/11/29

Y1 - 2020/11/29

N2 - The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium–glucose co-transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given:. • Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin are recommended for the prevention of HF hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or at high cardiovascular risk. • Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalization and cardiovascular death in symptomatic patients with HF and reduced ejection fraction already receiving guideline-directed medical therapy regardless of the presence of type 2 diabetes mellitus.

AB - The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium–glucose co-transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given:. • Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin are recommended for the prevention of HF hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or at high cardiovascular risk. • Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalization and cardiovascular death in symptomatic patients with HF and reduced ejection fraction already receiving guideline-directed medical therapy regardless of the presence of type 2 diabetes mellitus.

KW - Cardiovascular outcomes

KW - Heart failure

KW - Renal function

KW - Sodium–glucose co-transporter 2 inhibitors

KW - Type 2 diabetes mellitus

U2 - 10.1002/ejhf.2026

DO - 10.1002/ejhf.2026

M3 - Article

C2 - 33068051

AN - SCOPUS:85094593637

VL - 22

SP - 1984

EP - 1986

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 11

ER -

Heart Failure Association of the European Society of Cardiology update on sodium–glucose co-transporter 2 inhibitors in heart failure

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this